Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Oguchi T, Kanayama Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Shioura T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. Among authors: takagi h. Mod Rheumatol. 2018 Jan;28(1):119-125. doi: 10.1080/14397595.2017.1317320. Epub 2017 May 2. Mod Rheumatol. 2018. PMID: 28463029
Measurement of the cervical spinal cord volume on MRI.
Yanase M, Matsuyama Y, Hirose K, Takagi H, Yamada M, Iwata H, Ishiguro N. Yanase M, et al. Among authors: takagi h. J Spinal Disord Tech. 2006 Apr;19(2):125-9. doi: 10.1097/01.bsd.0000181294.67212.79. J Spinal Disord Tech. 2006. PMID: 16760787 Clinical Trial.
Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study.
Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Terabe K, Fukaya N, Kanayama Y, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Fujibayashi T, Kojima M, Ishiguro N; TBC. Kojima T, et al. Among authors: takagi h. Mod Rheumatol. 2012 Jun;22(3):339-45. doi: 10.1007/s10165-011-0518-4. Epub 2011 Sep 3. Mod Rheumatol. 2012. PMID: 21892671
Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.
Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, Yabe Y, Kato T, Terabe K, Fukaya N, Tsuchiya H, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Ishiguro N. Kojima T, et al. Among authors: takagi h. Mod Rheumatol. 2012 Jun;22(3):370-5. doi: 10.1007/s10165-011-0528-2. Epub 2011 Sep 20. Mod Rheumatol. 2012. PMID: 21931942
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
Takahashi N, Kojima T, Terabe K, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. Takahashi N, et al. Among authors: takagi h. Mod Rheumatol. 2013 Sep;23(5):904-12. doi: 10.1007/s10165-012-0760-4. Epub 2012 Sep 14. Mod Rheumatol. 2013. PMID: 22975734
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N. Kojima T, et al. Among authors: takagi h. Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26. Mod Rheumatol. 2013. PMID: 23099471
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kanayama Y, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Terabe K, Yoshioka Y, Ishiguro N. Takahashi N, et al. Among authors: takagi h. Clin Rheumatol. 2014 Jan;33(1):39-47. doi: 10.1007/s10067-013-2392-2. Epub 2013 Sep 22. Clin Rheumatol. 2014. PMID: 24057092 Free PMC article.
Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H, Kojima T, Kaneko A, Hirano Y, Ishikawa H, Hattori Y, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Fukaya N, Kanayama Y, Shioura T, Hayashi M, Fujibayashi T, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Terabe K, Ishiguro N. Matsubara H, et al. Among authors: takagi h. J Rheumatol. 2014 Aug;41(8):1583-9. doi: 10.3899/jrheum.130901. Epub 2014 Jul 15. J Rheumatol. 2014. PMID: 25028370
Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Hayashi M, Tsuboi S, Kanayama Y, Funahashi K, Hanabayashi M, Hirabara S, Asai S, Yoshioka Y, Ishiguro N. Takahashi N, et al. Among authors: takagi h. Rheumatology (Oxford). 2015 May;54(5):854-9. doi: 10.1093/rheumatology/keu418. Epub 2014 Oct 21. Rheumatology (Oxford). 2015. PMID: 25339638
3,549 results